Report Sections

See All Reports

  • HP:0000859: Hyperaldosteronism
  • Pneumonia (382) Neoplasm (47) Respiratory tract infection (46) Diabetes mellitus (39) Abnormality of the cardiovascular system (39) Depressivity (35) Abnormal lung morphology (33) Hypoxemia (30) Acute kidney injury (29) Hypertension (25) Thromboembolism (23) Myocardial infarction (22) Anosmia (21) Mental deterioration (21) Arthritis (20) Type II diabetes mellitus (20) Chronic pulmonary obstruction (19) Leukemia (18) Pulmonary fibrosis (18) Pulmonary obstruction (18) Abnormality of the kidney (17) Stroke (17) Congestive heart failure (16) Abnormality of coagulation (16) Pulmonary embolism (16) Neoplasm of the lung (16) Rheumatoid arthritis (15) Asthma (15) Interstitial pneumonitis (15) Crohn's disease (15) Autistic behavior (14) Chronic pain (14) Type I diabetes mellitus (13) Deep venous thrombosis (12) Ulcerative colitis (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Carcinoma (11) Alzheimer disease (10) Lymphoma (10) Chronic kidney disease (10) Myocarditis (10) Low levels of vitamin D (10) Sepsis (10) Renal insufficiency (9) Dementia (9) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Weight loss (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Behavioral abnormality (8) Psychosis (8) Infertility (8) Abnormality of the gastrointestinal tract (8) Migraine (7) Breast carcinoma (7) Psoriasiform dermatitis (7) Peripheral arterial stenosis (7) Fatigue (7) Schizophrenia (7) Encephalopathy (6) Lymphopenia (6) Dysphagia (6) Bronchiectasis (6) Immunodeficiency (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Obstructive sleep apnea (6) Sleep apnea (6) Prostate cancer (6) Non-small cell lung carcinoma (6) Neoplasm of the large intestine (6) Seizure (5) Premature birth (5) Difficulty walking (5) Gastroparesis (5) Neoplasm of the pancreas (5) Autoimmunity (5) Knee osteoarthritis (5) Disseminated intravascular coagulation (5) Lymphoid leukemia (5) Inflammatory abnormality of the skin (5) Neoplasm of head and neck (5) Allergy (5) Eczema (4) Atopic dermatitis (4) Hepatic fibrosis (4) Cardiac arrest (4) Abnormality of blood and blood-forming tissues (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Headache (4) Colon cancer (4) Reduced factor VIII activity (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Renal cell carcinoma (4) Abnormal anterior horn cell morphology (4) Attention deficit hyperactivity disorder (4) Amyotrophic lateral sclerosis (4) Arrhythmia (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Abnormality of the eye (3) Obsessive-compulsive behavior (3) Abnormality of the endocrine system (3) Spastic diplegia (3) Polyneuropathy (3) Meningitis (3) Hepatic steatosis (3) Abnormal heart morphology (3) Cardiomyopathy (3) Tachycardia (3) Fever (3) Hypothermia (3) Apnea (3) Celiac disease (3) Myelodysplasia (3) Acute myeloid leukemia (3) Myeloproliferative disorder (3) Chronic lymphatic leukemia (3) Multiple myeloma (3) Cystoid macular edema (3) Postprandial hyperglycemia (3) Cutaneous melanoma (3) Small cell lung carcinoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Bulimia (3) Hypogeusia (2) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Periodontitis (2) Agoraphobia (2) Nephrolithiasis (2) Abnormality of the thyroid gland (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Keratoconjunctivitis sicca (2) Spasticity (2) Hemiparesis (2) Abnormal joint morphology (2) Aortic valve stenosis (2) Angina pectoris (2) Pancreatitis (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Male infertility (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Chronic bronchitis (2) Lymphoproliferative disorder (2) Intervertebral disc degeneration (2) Stomatitis (2) Stridor (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) B-cell lymphoma (2) Myeloid leukemia (2) Bronchitis (2) Pain (2) Cervix cancer (2) Cholangitis (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Abnormality of the nervous system (1) Aggressive behavior (1) IgA deposition in the glomerulus (1) Oligospermia (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Syncope (1) Cerebral hemorrhage (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Iron deficiency anemia (1) Anemia (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Hyperkalemia (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Myelomeningocele (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Vascular dilatation (1) Recurrent E. coli infections (1) Osteomyelitis (1) Tachypnea (1) Central apnea (1) Embryonal neoplasm (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Allergic rhinitis (1) Skeletal muscle atrophy (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Enterocolitis (1) Intermittent claudication (1) Thrombophlebitis (1) Supraventricular tachycardia (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Spontaneous abortion (1) Venous insufficiency (1) Monoclonal immunoglobulin M proteinemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Uterine neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) Ciliary dyskinesia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Rhinitis (1) Seasonal allergy (1) Hypercapnia (1) Restless legs (1) Non-Hodgkin lymphoma (1) Membranous nephropathy (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Ductal carcinoma in situ (1) Heart murmur (1) Cardiogenic shock (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Brain neoplasm (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Sarcoma (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Rectal fistula (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Halitosis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0000859: Hyperaldosteronism

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (3)


    Name (Synonyms) Correlation
    drug4368 The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki 1.00
    drug460 Azithromycin Tablets Wiki 0.71
    drug1970 Hydroxychloroquine Sulfate Wiki 0.29

    Correlated MeSH Terms (20)


    Name (Synonyms) Correlation
    D006929 Hyperaldosteronism NIH 1.00
    D054559 Hyperphosphatemia NIH 1.00
    D004314 Down Syndrome NIH 1.00
    Name (Synonyms) Correlation
    D007008 Hypokalemia NIH 1.00
    D008595 Menorrhagia NIH 1.00
    D000309 Adrenal Insufficiency NIH 1.00
    D001997 Bronchopulmonary Dysplasia NIH 0.71
    D014552 Urinary Tract Infections NIH 0.71
    D009080 Mucocutaneous Lymph Node Syndrome NIH 0.58
    D001289 Attention Deficit Disorder with Hyperactivity NIH 0.50
    D006470 Hemorrhage NIH 0.50
    D020141 Hemostatic Disorders NIH 0.25
    D001778 Blood Coagulation Disorders NIH 0.25
    D006973 Hypertension NIH 0.20
    D004194 Disease NIH 0.16
    D013577 Syndrome NIH 0.09
    D003141 Communicable Diseases NIH 0.07
    D007239 Infection NIH 0.05
    D045169 Severe Acute Respiratory Syndrome NIH 0.04
    D018352 Coronavirus Infections NIH 0.03

    Correlated HPO Terms (7)


    Name (Synonyms) Correlation
    HP:0002905 Hyperphosphatemia HPO 1.00
    HP:0000132 Menorrhagia HPO 1.00
    HP:0002900 Hypokalemia HPO 1.00
    Name (Synonyms) Correlation
    HP:0000846 Adrenal insufficiency HPO 1.00
    HP:0007018 Attention deficit hyperactivity disorder HPO 0.50
    HP:0001928 Abnormality of coagulation HPO 0.25
    HP:0000822 Hypertension HPO 0.20

    Clinical Trials

    Navigate: Correlations   HPO

    There is one clinical trial.


    1 Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

    The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

    NCT04278404
    Conditions
    1. Coronavirus Infection (COVID-19)
    2. Pulmonary Arterial Hypertension
    3. Urinary Tract Infections in Children
    4. Hypertension
    5. Pain
    6. Hyperphosphatemia
    7. Primary Hyperaldosteronism
    8. Edema
    9. Hypokalemia
    10. Heart Failure
    11. Hemophilia
    12. Menorrhagia
    13. Insomnia
    14. Pneumonia
    15. Skin Infection
    16. Arrythmia
    17. Asthma in Children
    18. Bronchopulmonary Dysplasia
    19. Adrenal Insufficiency
    20. Fibrinolysis; Hemorrhage
    21. Attention Deficit Hyperactivity Disorder
    22. Multisystem Inflammatory Syndrome in Children (MIS-C)
    23. Kawasaki Disease
    24. Coagulation Disorder
    25. Down Syndrome
    Interventions
    1. Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    MeSH:Infection Communicable Diseases Urinary Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome Bronchopulmonary Dysplasia Down Syndrome Menorrhagia Hypertension Hemostatic Disorders Mucocutaneous Lymph Node Syndrome Blood Coagulation Disorders Hyperphosphatemia Hypokalemia Adrenal Insufficiency Hyperaldosteronism Disease Syndrome Hemorrhage Attention Deficit Disorder with Hyperactivity
    HPO:Abnormality of coagulation Abnormality of the coagulation cascade Adrenal insufficiency Attention deficit hyperactivity disorder Hyperaldosteronism Hyperphosphatemia Hypertension Hypokalemia Menorrhagia Primary hyperaldosteronism

    Primary Outcomes

    Measure: Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Elimination rate constant (ke) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Half-life (t1/2) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Absorption rate constant (ka) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: AUC (area under the curve) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Maximum concentration (Cmax) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Time to achieve maximum concentration (Tmax) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook